MASH and Cardiovascular-Kidney-Metabolic Crosstalk

Mar 06–09, 2028 | NTUH International Convention Center, Taipei, TPE, Taiwan
Scientific Organizers: Bart Staels, Jia-Horng Kao, Alina M. Allen, and Kai-Chien Yang

  Livestream
  In Person
  On Demand
×

-

Mar 06–09, 2028 | NTUH International Convention Center, Taipei, TPE, Taiwan

Scientific Organizers: Bart Staels, Jia-Horng Kao, Alina M. Allen, and Kai-Chien Yang

Supported by:  
Important Deadlines
Early Registration Deadline: Deadlines not yet available for this meeting.
Scholarship Deadline: Deadlines not yet available for this meeting.
Short Talk Abstract Deadline: Deadlines not yet available for this meeting.
Poster Abstract Deadline: Deadlines not yet available for this meeting.
Meeting Summary

Metabolic dysfunction-associated steatohepatitis (MASH) is a systemic disease in which hepatic injury both reflects and amplifies cardiovascular, kidney, adipose, and metabolic dysfunction. Patients with MASH have increased risks of diabetes, cardiovascular disease, chronic kidney disease, and other extrahepatic complications, highlighting the need for integrating a cardiovascular-kidney-liver-metabolic (CKLM) framework rather than an organ-by-organ focus.


This Keystone Symposia conference on MASH and Cardiovascular-Kidney-Metabolic Crosstalk will define how the liver participates in whole-body homeostasis and how bidirectional organ crosstalk shapes MASH onset, progression, and clinical outcomes. It will connect human genetics, immune and fibrotic mechanisms, endocrine and metabolic signaling, experimental models, and clinical phenotypes to identify shared pathways, biomarkers, and therapeutic targets across organs.


The conference will bring together hepatologists, cardiologists, nephrologists, endocrinologists, immunologists, geneticists, data scientists, and industry investigators to address (1) mechanisms of liver-heart-kidney-adipose-gut communication, (2) clinical trajectories and high-risk phenotypes, (3) human genetics and multi-omics that link targets across organ systems, and (4) pharmacologic strategies with whole-patient benefit.


MASH and related CKLM diseases are increasing worldwide, while clinical care, experimental models, and drug development remain fragmented. By integrating mechanistic, translational, clinical, and therapeutic perspectives—and by engaging scientific leaders from Asia, Europe, and North America—this conference will establish a forward-looking agenda for MASH-centered, multi-organ research and care.


Unique Career Development Opportunities

This meeting will feature a Career Roundtable where trainees and early-career investigators will have the opportunity to interact with field leaders from across academic and industry sectors for essential career development advice and networking opportunities. Find out more about Career Roundtables here: https://www.keystonesymposia.org/diversity/career-development-initiatives

KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS

Subscribe for Updates